DCM
KYTX icon

Discovery Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Discovery Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,000
Closed -$122K – 95
2024
Q3 		$122K Hold
25,000
– – 0.01% 59
2024
Q2 		$188K Hold
25,000
– – 0.02% 52
2024
Q1 		$621K Buy
+25,000
New +$698K 0.08% 48

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Discovery Capital Management's KYTX Position: Q4 2024 in Review

Discovery Capital Management sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 25,000 shares — an estimated $122K sold.

Discovery Capital Management first reported a position in KYTX in Q1 2024 and held it in 3 quarters. The position peaked at $621K in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • Discovery Capital Management reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Discovery Capital Management sold 25,000 Kyverna Therapeutics shares in Q4 2024, an estimated $122K.
  • Discovery Capital Management first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 3 quarters.
  • Discovery Capital Management's Kyverna Therapeutics position peaked at $621K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on Discovery Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.